Merck publish series of T-Type Calcium Channel blockers

Merck have published a series of  T-Type Calcium Channel blockers

FDA approves Exforge and Diovan HCT

The US FDA has approved Diovan HCT (valsartan/hydrochlorothiazide) and Exforge (amlodipine/ valsartan), as first-line therapies in patients who need multiple drugs to achieve their blood pressure goals.

Ore acquire tiapamil from Roche

Ore Pharmaceuticals have acquired Ca channel antagonist tiapamil from Roche. The company plan to develop the drug for CNS indications

Cleviprex approved in US

The FDA has approved The Medicines Company’s ca channel blocker Cleviprex for the IV treatment of hypertension

Cleviprex effective in the treatment of Acute Hypertension After Cardiac Surgery

Phase III data shows that The Medicines Company’s drug Cleviprex (clevidipine butyrate) is effective and safe in the rapid treatment of acute hypertension after cardiac surgery.

Cleviprex controls perioperative hypertension, may reduce heart attack

Data presented at the SCA Meeting show The Medicine Company’s Calcium channel antagonist Cleviprex injectable may reduce the risk of heart attack compared to two other antihypertensive agents.

Cleviprex shown to reduce and control high blood pressure in elderly patients

Cleviprex (clevidipine), produced The Medicines Company, has been shown to rapidly achieve and maintain blood pressure control in patients with acutely elevated blood pressure

Newron completes Phase III recruitment for Safinamide in Parkinsons

Newron completes Phase III recruitment for Safinamide in Parkinsons

Exforge treatment effective in black patients

Black patients treated with Exforge (Amlodipine/Valsartan) have been show to experience a significantly higher reduction in systolic blood pressure than those on amlodipine alone

Icagen report on Ion Channel Progress

ICA-105665 KCNQ channel opener for epilepsy – Single ascending dose Phase I trial completed; multiple ascending dose Phase I initiated
Senicapoc for Asthma – Phase I trial initiated
Na and Ca channel Pain Program – Leads identified

Phase II trials for both projects expected in the second half of 2008